DBV Technologies (DBVT) to Release Earnings on Thursday

DBV Technologies (NASDAQ:DBVT) will likely be releasing its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect DBV Technologies to post earnings of ($0.1935) per share and revenue of $1.0570 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 12, 2026 at 7:00 AM ET.

DBV Technologies Stock Performance

NASDAQ DBVT opened at $21.87 on Wednesday. The company has a market cap of $1.20 billion, a PE ratio of -4.23 and a beta of -0.97. The firm’s 50 day moving average price is $20.74 and its 200-day moving average price is $15.91. DBV Technologies has a 52-week low of $3.82 and a 52-week high of $26.18.

Insider Transactions at DBV Technologies

In related news, major shareholder Bpifrance Epic sold 1,292,103 shares of the company’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $4.19, for a total transaction of $5,413,911.57. Following the completion of the sale, the insider owned 7,303,369 shares of the company’s stock, valued at approximately $30,601,116.11. This represents a 15.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders have sold 3,369,627 shares of company stock worth $15,489,908. 1.44% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Ikarian Capital LLC acquired a new stake in shares of DBV Technologies during the fourth quarter worth about $10,064,000. Vestal Point Capital LP acquired a new position in shares of DBV Technologies during the 4th quarter worth about $5,751,000. Squadron Capital Management LLC purchased a new position in DBV Technologies in the fourth quarter valued at approximately $4,601,000. Millennium Management LLC grew its position in shares of DBV Technologies by 89.7% in the 4th quarter. Millennium Management LLC now owns 640,885 shares of the company’s stock valued at $12,286,000 after buying an additional 303,022 shares during the last quarter. Finally, Engineers Gate Manager LP purchased a new position in shares of DBV Technologies during the fourth quarter worth about $479,000. 71.74% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. HC Wainwright set a $40.00 price objective on DBV Technologies in a research report on Thursday, December 18th. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a report on Wednesday, December 17th. Guggenheim reiterated a “buy” rating and issued a $51.00 price target (up from $35.00) on shares of DBV Technologies in a report on Wednesday, December 17th. Citizens Jmp increased their price target on DBV Technologies from $21.00 to $45.00 and gave the stock a “market outperform” rating in a research report on Wednesday, December 17th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DBV Technologies in a report on Monday, December 29th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, DBV Technologies currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.25.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.